MYL6B

MYL6B (MLC1sa) is a myosin alkali essential light chain that arose by gene duplication from a nonmuscle light chain isoform and is expressed at the onset of myogenesis while remaining detectable in nonmuscle cells (PMID:2304459). It is functionally distinguished from other alkali light chains by its N-terminal lobe, which governs isoform-specific sorting: MYL6B shows only weak sarcomeric targeting in cardiomyocytes and is otherwise distributed throughout the cytoplasm, and chimeric mapping localizes this sorting determinant to the N-terminal lobe (PMID:8856505). In slow muscle fibers its expression level is inversely related to maximal shortening velocity, and fibers carrying MYL6B without the MLC1Sb isoform generate greater isometric force, marking it as a modulator of contractile mechanics (PMID:16884681). Beyond muscle, MYL6B binds the first IQ motif of IQGAP1, with transient interactions to the first IQ motifs of IQGAP2 and IQGAP3 (PMID:18587628, PMID:21299499). As a light-chain subunit of non-muscle myosin II holoenzymes, MYL6B binds both MDM2 and p53 and facilitates MDM2-mediated ubiquitination and degradation of p53; this requires its incorporation into functional NMII, since inhibiting myosin II heavy-chain ATPase blocks the effect, and MYL6B loss reduces clonogenicity and increases apoptosis in hepatocellular carcinoma cells (PMID:29439719). Consistent with a pro-tumorigenic role, MYL6B knockdown in rectal adenocarcinoma cells suppresses proliferation, migration, and invasion and reverses EMT marker patterns (PMID:33817240).

1. 1990 Medium

   Established MYL6B as a distinct myosin alkali light chain isoform of duplication origin, defining the gene's molecular identity and expression breadth across muscle and nonmuscle cells.

   Evidence cDNA cloning, sequencing, and isoform-specific expression profiling across species and tissues

   PMID:2304459

   Open questions at the time

   • Functional distinctiveness inferred from sequence rather than biochemical assay
   • No direct demonstration of light-chain binding to a myosin heavy chain at this stage
2. 1996 High

   Resolved how isoform-specific localization is encoded, showing MYL6B sorts only weakly to sarcomeres and that the N-terminal lobe carries the sorting determinant.

   Evidence Double epitope-tagging competition and chimeric cDNA expression in rat cardiomyocytes with confocal microscopy

   PMID:8856505

   Open questions at the time

   • Molecular partner mediating N-terminal lobe sorting not identified
   • Behavior in nonmuscle cell types not addressed
3. 1999 Low

   Correlated MYL6B abundance with declining contractile velocity during aging, supporting a role in tuning slow-fiber mechanics.

   Evidence 2D gel quantification of MLC isoform ratios in aging rat soleus with thyroid hormone treatment, correlated to published velocity data

   PMID:10632633

   Open questions at the time

   • Correlative only; velocity not measured in the same fibers, so velocity modulation is inferred not demonstrated
   • Thyroid hormone effects did not parallel velocity changes
4. 2006 Medium

   Provided direct functional evidence that MYL6B level inversely sets maximal shortening velocity and raises isometric force in slow fibers.

   Evidence Single-fiber mechanics correlated with MLC isoform composition by gel electrophoresis in pig diaphragm

   PMID:16884681

   Open questions at the time

   • Single species and lab
   • Mechanism by which the light chain alters velocity/force not resolved
5. 2011 Medium

   Mapped MYL6B binding specificity to the first IQ motif across the IQGAP family, defining a scaffold-interaction interface beyond myosin.

   Evidence Native gel electrophoresis with synthetic IQ-motif peptides from IQGAP1/2/3 and molecular modelling

   PMID:18587628 PMID:21299499

   Open questions at the time

   • Interactions with IQGAP2/3 are transient and shown by a single method
   • Functional consequence of IQGAP binding not established
6. 2018 High

   Connected MYL6B to tumor cell survival by showing it facilitates MDM2-p53 binding and p53 degradation in an NMII-dependent manner.

   Evidence Co-IP/MS, ubiquitination assay, myosin II ATPase inhibition, CRISPR knockout, clonogenic and apoptosis assays in HCC cells

   PMID:29439719

   Open questions at the time

   • Structural basis of the MYL6B-MDM2-p53 ternary arrangement unknown
   • How NMII enzymatic activity couples to p53 ubiquitination mechanistically unresolved
7. 2020 Medium

   Extended the pro-tumorigenic role to EMT, showing MYL6B promotes proliferation, invasion, and mesenchymal marker expression.

   Evidence siRNA knockdown with proliferation, migration/invasion, apoptosis assays and EMT marker Western blots in rectal adenocarcinoma cells

   PMID:33817240

   Open questions at the time

   • No mechanistic pathway placement beyond EMT markers
   • Link to the p53 axis in this cancer context not tested

• How MYL6B's distinct biophysical contribution to myosin mechanics relates to its scaffolding (IQGAP) and tumor-survival (NMII-MDM2-p53) functions remains unresolved.
• No structural model of MYL6B within NMII or bound to MDM2/p53
• Whether IQGAP binding and p53 regulation share a common cellular pathway is untested